COMPASS THERAPEUTICS INC (CMPX)
US20454B1044 - Common Stock
Taking everything into account, CMPX scores 3 out of 10 in our fundamental rating. CMPX was compared to 568 industry peers in the Biotechnology industry. CMPX has a great financial health rating, but its profitability evaluates not so good. CMPX does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year CMPX has reported negative net income.
CMPX had a negative operating cash flow in the past year.
In the past 5 years CMPX always reported negative net income.
CMPX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -32.02%, CMPX is in the better half of the industry, outperforming 65.66% of the companies in the same industry.
The Return On Equity of CMPX (-34.51%) is better than 76.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.02% | ||
| ROE | -34.51% | ||
| ROIC | N/A |
ROA(3y)-33.39%
ROA(5y)-54.26%
ROE(3y)-36.29%
ROE(5y)-98.05%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CMPX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CMPX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CMPX has been increased compared to 5 years ago.
There is no outstanding debt for CMPX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
CMPX has an Altman-Z score of 7.19. This indicates that CMPX is financially healthy and has little risk of bankruptcy at the moment.
CMPX has a better Altman-Z score (7.19) than 83.89% of its industry peers.
There is no outstanding debt for CMPX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 7.19 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
CMPX has a Current Ratio of 31.84. This indicates that CMPX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 31.84, CMPX belongs to the best of the industry, outperforming 97.70% of the companies in the same industry.
A Quick Ratio of 31.84 indicates that CMPX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 31.84, CMPX belongs to the top of the industry, outperforming 97.70% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 31.84 | ||
| Quick Ratio | 31.84 |
3. Growth
3.1 Past
The earnings per share for CMPX have decreased strongly by -12.12% in the last year.
EPS 1Y (TTM)-12.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
CMPX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 34.64% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-5.86%
EPS Next 2Y-13.22%
EPS Next 3Y-9.34%
EPS Next 5Y34.64%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CMPX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CMPX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as CMPX's earnings are expected to decrease with -9.34% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.22%
EPS Next 3Y-9.34%
5. Dividend
5.1 Amount
CMPX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
COMPASS THERAPEUTICS INC
NASDAQ:CMPX (12/20/2024, 8:02:56 PM)
After market: 1.38 0 (0%)1.38
+0.01 (+0.73%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners55.77%
Inst Owner Change-3.53%
Ins Owners6.38%
Ins Owner Change3.28%
Market Cap189.87M
Analysts86.15
Price Target8.16 (491.3%)
Short Float %1.47%
Short Ratio2.91
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)13.8%
Min EPS beat(2)-3.2%
Max EPS beat(2)30.79%
EPS beat(4)2
Avg EPS beat(4)10.89%
Min EPS beat(4)-14.56%
Max EPS beat(4)30.79%
EPS beat(8)5
Avg EPS beat(8)15.08%
EPS beat(12)7
Avg EPS beat(12)-2.3%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.66%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)19.66%
EPS NY rev (1m)16.32%
EPS NY rev (3m)16.32%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.57%
Revenue NY rev (3m)23.24%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 223.38 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.37 | ||
| P/tB | 1.37 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.37
EYN/A
EPS(NY)-0.44
Fwd EYN/A
FCF(TTM)-0.35
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS0.01
BVpS1.01
TBVpS1.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.02% | ||
| ROE | -34.51% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-33.39%
ROA(5y)-54.26%
ROE(3y)-36.29%
ROE(5y)-98.05%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 8.88% | ||
| Cap/Sales | 6.35% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 31.84 | ||
| Quick Ratio | 31.84 | ||
| Altman-Z | 7.19 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)120.93%
Cap/Depr(5y)77.91%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-5.86%
EPS Next 2Y-13.22%
EPS Next 3Y-9.34%
EPS Next 5Y34.64%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-15.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-26.6%
EBIT Next 3Y-7.47%
EBIT Next 5Y29.24%
FCF growth 1Y-65.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-70.7%
OCF growth 3YN/A
OCF growth 5YN/A